bio life sciences inc - BLFE

BLFE

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 18.17K

Last Updated:

Dec 31, 2025, 1:42 PM EDT

Company Overview: bio life sciences inc - BLFE

BLFE Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.01

Market Cap

$0.00

Shares Outstanding

4.83B

Public Float

3.50B

Beta

104.93

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.01

Yield

N/A

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

514.88K

 

BLFE Performance

1 Week
 
-99.00%
 
1 Month
 
0.00%
 
3 Months
 
0.00%
 
1 Year
 
0.00%
 
5 Years
 
N/A
 

BLFE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About bio life sciences inc - BLFE

Bio Life Sciences, Inc. provides healthcare, beauty, food and beverage industry services. It develops, licenses and distributes antimicrobial products and disruptive technology. The company was founded on March 31, 2000 and is headquartered in Henderson, NV.

BLFE At a Glance

Bio Life Sciences, Inc.
2831 Saint Rose Parkway
Henderson, Nevada 89052
Phone 1-833-919-1037 Revenue 411.70K
Industry Wholesale Distributors Net Income -1,267,738.00
Sector Distribution Services Employees N/A
Fiscal Year-end 11 / 2021
View SEC Filings

BLFE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 142.119
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -47.169
Enterprise Value to Sales 142.495
Total Debt to Enterprise Value 0.003

BLFE Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover 11.139

BLFE Liquidity

Current Ratio 0.094
Quick Ratio 0.094
Cash Ratio 0.046

BLFE Profitability

Gross Margin -239.143
Operating Margin -302.093
Pretax Margin -307.931
Net Margin -307.931
Return on Assets -3,430.12
Return on Equity N/A
Return on Total Capital 253.55
Return on Invested Capital N/A

BLFE Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -37.918
Total Debt to Total Assets 260.717
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio Life Sciences Inc - BLFE

Collapse All in section
All values USD millions. 2017 2018 2019 2020 5-year trend
Sales/Revenue
- - - 411.69K
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - 1.40M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - -
-
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - (984.54K)
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -239.14%
-
2017 2018 2019 2020 5-year trend
SG&A Expense
329.13K 42.28K 33.35K 259.16K
Research & Development
- - - -
-
Other SG&A
329.13K 42.28K 33.35K 259.16K
SGA Growth
+2,533.05% -87.15% -21.14% +677.16%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (47.44K)
-
EBIT after Unusual Expense
(329.13K) (42.28K) (33.35K) (1.20M)
Non Operating Income/Expense
- - - (22.15K)
-
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
11.26K 10.43K 13.60K 49.33K
Interest Expense Growth
+68.63% -7.33% +30.39% +262.66%
Gross Interest Expense
11.26K 10.43K 13.60K 49.33K
Interest Capitalized
- - - -
-
Pretax Income
(340.39K) (52.72K) (46.95K) (1.27M)
Pretax Income Growth
-1,675.16% +84.51% +10.94% -2,600.30%
Pretax Margin
- - - -307.93%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(340.39K) (52.72K) (46.95K) (1.27M)
Minority Interest Expense
- - - -
-
Net Income
(340.39K) (52.72K) (46.95K) (1.27M)
Net Income Growth
-1,675.16% +84.51% +10.94% -2,600.30%
Net Margin Growth
- - - -307.93%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(340.39K) (52.72K) (46.95K) (1.27M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(340.39K) (52.72K) (46.95K) (1.27M)
EPS (Basic)
-0.075 -0.0027 -0.0014 -0.0245
EPS (Basic) Growth
-63.76% +96.40% +48.15% -1,650.00%
Basic Shares Outstanding
4.45M 19.45M 34.45M 51.78M
EPS (Diluted)
-0.075 -0.0027 -0.0014 -0.0245
EPS (Diluted) Growth
-63.76% +96.40% +48.15% -1,650.00%
Diluted Shares Outstanding
4.45M 19.45M 34.45M 51.78M
EBITDA
- (329.13K) (33.35K) (1.24M)
EBITDA Growth
- - -2,533.04% -3,629.24%
-
EBITDA Margin
- - - -302.09%
-

Bio Life Sciences Inc in the News